Yazan Alsayed - Concepedia

Concepedia

Author

Yazan Alsayed

University of Arkansas for Medical Sciences

Also Known As

Y Al-Sayed, Y AlSayed, Y Alsayed, Y. Al-Sayed, Y. Alsayed, Yazan Alsayed, Yazan M. Alsayed

113

Publications

5.5K

Citations

33

H-Index

35

Concepts

All Affiliations

University of Arkansas for Medical Sciences Cancer Research And Biostatistics University of Illinois Chicago Harvard University Dana-Farber Cancer Institute

YA

About

Yazan Alsayed is an author at University of Arkansas for Medical Sciences specializing in medicine, immunology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	445
2	Health Sciences	4	4	319
3	Cell Biology	4	4	137
4	Allergy	1	1	26
5	Cellular Physiology	1	1	26

Yazan Alsayed

×

41

Publications

5.5K

Citations

33

H-Index

	Year	Citations
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 John D. Shaughnessy, Fenghuang Zhan, Bart Burington, Blood	2006	904
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma Yazan Alsayed, Hai T. Ngo, Judith Runnels, Blood	2006	470
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents Saad Z. Usmani, Christoph Heuck, Alyson E. Mitchell, Haematologica	2012	378
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 Bart Barlogie, Elias Anaissie, Frits van Rhee, British Journal of Haematology	2007	325
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities Bart Barlogie, Mauricio Pineda‐Roman, Frits van Rhee, Blood	2008	227
Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons Shahab Uddin, Beata Majchrzak, Joanna Woodson, Journal of Biological Chemistry	1999	226
Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance Bijay Nair, Frits van Rhee, John D. Shaughnessy, Blood	2010	200
High-risk myeloma is associated with global elevation of miRNAs and overexpression of <i>EIF2C2/AGO2</i> Yiming Zhou, Lijuan Chen, Bart Barlogie, Proceedings of the National Academy of Sciences	2010	197
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Blood	2007	183
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 John D. Shaughnessy, Pingping Qu, Saad Z. Usmani, Blood	2011	175

Page 1